Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MUC16 ARTEMIS T-cell therapy
- Development stage
- Preclinical
- Lead developer
- Eureka Therapeutics
- Modality
- TCR-Engineered T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
MUC16 ARTEMIS T-cell therapy is an investigational cell therapy developed by Eureka Therapeutics in partnership with Bristol Myers Squibb (via its subsidiary Juno Therapeutics). The therapy utilizes Eureka's proprietary ARTEMIS platform, which is designed to mimic the natural T-cell receptor (TCR) signaling complex rather than the traditional chimeric antigen receptor (CAR) structure. By utilizing a TCR-like signaling mechanism, ARTEMIS T cells aim to provide high specificity and potency against Mucin-16 (MUC16) expressing tumors, such as ovarian cancer, while potentially reducing the risk of severe cytokine release syndrome (CRS). MUC16, also known as CA-125, is a well-validated biomarker and therapeutic target that is highly expressed in the majority of epithelial ovarian cancers.
- Other names
- MUC16 T CellsMUC-16 T CellsMUC 16 T CellsEureka MUC16 T-cell therapyARTEMIS MUC16 T-cell therapy
02
Targets
MUC16 (Mucin-16)
Beyond the preview
Go deeper on MUC16 ARTEMIS T-cell therapy.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MUC16 ARTEMIS T-cell therapy.